Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-cohort neoadjuvant and adjuvant IO102-IO103 + pembrolizumab in resectable melanoma and SCCHN
2022-502787-20-00Phase 2Completed
- Sponsor
- IO Biotech
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of PD-L1/IDO peptide vaccine and pembrolizumab in melanoma and head and neck squamous cell carcinoma (HNSCC), sponsored by IO Biotech. Primary endpoint: Major pathological response (MPR). Started Aug 2023; status: completed.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-502787-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502787-20-00.